EAIS A.I CyberSecurity Scoring
19/11/2025
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for European Algae Industry Summit 2025 in 2026.
No incidents recorded for European Algae Industry Summit 2025 in 2026.
No incidents recorded for European Algae Industry Summit 2025 in 2026.
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
Latest updates, reports, and threat intel affecting the global network.
OliveTin gives access to predefined shell commands from a web interface. The `filterToDefinedArgumentsOnly` function in the executor is intended to discard any arguments not explicitly defined in the action's configuration. However, prior to commit ebffd9f040f791208aee1db2e5a8aecd1e3e603d, a special case allows any argument whose name starts with `ot_` to bypass this filter. While two system arguments (`ot_executionTrackingId` and `ot_username`) are injected by OliveTin and overridden, all other `ot_`-prefixed arguments supplied by the user pass through unmodified. These bypassed arguments are not type-checked — the validation loop only iterates over the action's defined arguments, so `ot_`-prefixed arguments skip all type safety checks entirely; set as environment variables — via `buildEnv()`, with completely unvalidated values, and passed to the executed command; and included in the template context — available as `.Arguments.ot_*` in template rendering. Commit ebffd9f040f791208aee1db2e5a8aecd1e3e603d contains a patch.
WeeChat (Wee Enhanced Environment for Chat) is a free chat client. In versions 0.3.1 through 4.9.0, the WeeChat relay authentication uses non-constant-time string comparison functions (weechat_strcasecmp and strcmp) to verify password hashes and plaintext passwords. An attacker can exploit timing differences to extract the server-computed hash character by character, then authenticate using the correct hash without knowing the password. Version 4.9.1 fixes the issue.
WeeChat (Wee Enhanced Environment for Chat) is a free chat client. In versions 4.3.0 through 4.9.0, the WeeChat relay module's WebSocket permessage-deflate decompression function relay_websocket_inflate() has no upper bound on output size. An authenticated relay user can send a small compressed WebSocket frame (~100 bytes) that decompresses to gigabytes, exhausting all server memory and crashing the entire WeeChat process. The api protocol enables permessage-deflate and requires authentication before WebSocket upgrade. Version 4.9.1 patches the issue.
FORT Validator is a Resource Public Key Infrastructure (RPKI) relying-party validator that produces validated route-origin data. FORT Validator versions through 1.6.7 contain an origin-validation error in their RRDP processing: a delegated CA under the same Trust Anchor Locator (TAL) can reference a victim CA’s public RRDP notification and snapshot URLs, causing FORT’s URL-based download cache to report success after deleting the victim’s local snapshot. Following a routine victim publication, this can silently remove the victim’s VRPs and other signed objects from FORT’s output, potentially enabling route hijacking or loss of reachability. Version 1.6.8 contains a patch that rejects cross-origin RRDP snapshot and delta URLs; as a workaround, administrators can disable HTTP/RRDP with --http.enabled=false while keeping rsync enabled, although this can leave data unavailable or stale where rsync is not supported.
Recce is a data-validation toolkit for enhanced dbt (data build tool) PR review. Prior to version 1.50.0, OSS server deployments that expose the server to an untrusted network without authentication are vulnerable to unauthenticated SQL execution through the query run API. When Recce is configured with a DuckDB-backed project, an attacker can use DuckDB filesystem primitives to read and write files accessible to the Recce server process. The impact depends on how Recce is deployed, but may include disclosure of local files, tampering with Recce/dbt artifacts, modification of browser-served static files leading to stored XSS, and modification of application files if those paths are writable. If Recce is run as root, file access occurs with root privileges inside that host or container. This issue has been patched in Recce `v1.50.0`. Users should upgrade to Recce `v1.50.0` or later. The patch restricts unsafe file read/write behavior for DuckDB-backed query execution and hardens the affected query path. Other warehouse adapters have also been reviewed for similar exposure. Users who cannot upgrade immediately should avoid exposing `recce server` to the public internet or any untrusted network. Recommended mitigations include enabling authentication or placing Recce behind an authenticated reverse proxy/VPN, running Recce as a non-root user, using a read-only application filesystem where possible, and ensuring that sensitive files or credentials are not available to the Recce process.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.